Studies Enrolling Volunteers


This chart below is a summary of all actively enrolling studies. If you are interested in participating in a research study, please contact Latasha Chapman at 404-727-6050 or latasha.chapman@emory.edu.

Research StudyEligibility Criteria
Emory Alzheimer's Disease Research Center Honor Research Registry
Longitudinal study of changes in memory and other cognitive skills
  • Aging people with no memory problems
  • People of any age with MCI, Alzheimer's disease or other forms of dementia
  • Willing to participate in additional research studies
  • Study partner available to participate in visits
ACTC Brain Donation Program
  • Previous participation in previous ACTC clinical study
ADNI4
  • Underrepresented minorities
  • Ages: 65-90
ALLFTD
  • FTLD diagnosis
  • Age: 30+
APEX
  • Preclinical AD Consented to AHEAD, but screen failed
  • Ages: 55-88
CEP
  • Clinic patient with MCI

EHAS

  • Read and speak English fluently
  • Age: 18+

EHBS

  • Currently enrolled in the Emory Healthy Aging Study (EHAS)
  • Ages: 50-75
GIN-Cognitive
  • Study enrollment includes individuals over the age of 18. Participation is open to all genders, races, and ethnicities. All patients seen by an Emory Brain Health provider or an Emory Primary Care provider. If the potential participant has cognitive decline, they will need a care partner to accompany them during their visit. Also, the potential participant does not have to have brain health disease to qualify if they have an Emory medical record.
  • Age: 18+
HOPE
  • Alzheimer's disease diagnosis with at least 6-month decline in cognitive function
  • MMSE score 15-28
  • Available/consenting Study Partner
  • Able to identify a Legally Authorized Representative (LAR)
  • Stable chronic conditions at least 30 days
  • Formal education of 8 or more years
  • Adequate vision and hearing
  • Mobility sufficient for compliance with testing procedures (ambulatory or aided-ambulatory, i.e. cane or walker)
  • Ages: 50-90
LEADS - Longitudinal Early-onset Alzheimer's Disease Study Protocol
  • Normal: CDR = 0
  • Normal: MMSE 26-30
  • EOAD: CDR ≤ 1.0
  • Ages: 40-64
HONOR/ Memory/ UDS
  • Cognitively Normal; MCI; PD Minorities, specifically AA (not necessarily for PD cohort)
  • Willing to do LP, MRI
  • Age: Over 70 years Old
Pak
  • AD diagnosis
  • Age: 18+
Pak - Citosleep
  • Diagnosis of Mild Cognitive Impairment (MCI) or Requires a study partner
  • Subjective Memory Complaints Have Internet and email access
  • Age: Over 50 years old
PAN
  • No prior diagnosis of dementia or psychiatric illness
  • lives independently
  • no contraindications to MRI
  • Ages: 50-79
STAND
  • African American Study Subjective memory concerns
  • MoCA score 15-25
  • Age: Over 50 years old
SuperAger
  • TICS score must be > 33
  • Age: 80+

Contact Us

Latasha Chapman

Please contact our clinical research coordinator for more information.

Phone:
(404)-727-6050
Email:
latasha.chapman@emory.edu

Detailed Descriptions of Research Studies and Clinical Trials

James Lah, MD, PhD
Clinical Core Leader, Emory Alzheimer's Disease Research Center

Felicia Goldstein, PhD
Clinical Core Co-Leader, Emory Alzheimer's Disease Research Center

The purpose of Honor is to have a group of volunteers who want to participate in future research studies on memory & thinking. By joining Honor you will learn about new research studies that are seeking volunteers. You will also receive our newsletter and invitations to educational events.

All Honor volunteers must have a “study partner” accompany them to their research visit. Your study partner will be asked questions about your memory and thinking. They will also be asked about your day to day functioning. A study partner is someone who has at least 10 hours of contact with you each week.

For more information about this research study, please call Samantha Heldenberg at 404-712-7542 or email shelden@emory.edu.

Allan Levey, MD, PhD
Director, Emory Alzheimer's Disease Research Center
Emory University Department of Neurology

Long-term study (2-4 years) being conducted as part of the Alzheimer’s Disease Neuroimaging Initiative to characterize changes in the brain associated with MCI and AD. Subjects will under multiple MRI and PET scans, lumbar puncture, blood draws and cognitive testing.

For more information about this research study, please call Becky Byram at 404-712-0195 or email rbyram@emory.edu.

Allan Levey, MD, PhD

This multinational study is using a placebo or the study drug, to determine safety and efficacy and to explore the dose response of this drug. In this 18-month study, a drug/placebo is infused biweekly (once every 2 weeks). Subjects will be from 2 clinical subgroups: MCI due to Alzheimer's disease (AD) or mild Alzheimer's disease dementia. Effectiveness of drug treatment will be assessed using cognitive tests, as well as biological markers (MRI, PET, CSF, blood).

For more information about this research study, please call Michelle Wiles at 404-778-0664 or email mkwiles@emory.edu.

View BAN2401-301 study website

Ihab Hajjar, MD

The study will consist of a screening period of up to 12 weeks in length following the signing of informed consent. Eligible patients will then undergo baseline visit assessments (Day 1) prior to receiving the first dose of blinded study drug (gantenerumab or placebo). Patients will continue in the double-blind treatment period for 104 weeks.

For more information about this research study, please call Aaron Milloy at 404-712-6855 or email aaron.m.milloy@emory.edu.

For more information about this research study, please call William Hu at 404-727-4174 or email wthu@emory.edu.

James Lah, MD, PhD

This study is the largest clinical research study every conducted it Atlanta. It is designed to further our scientific understanding of how we age so we can better understand, prevent and treat diseases of aging. To participate, simply sign up online at www.healthyaging.emory.edu, complete a brief health history questionnaire and occasionally respond to various surveys and complete online memory tasks.

For more information about this research study, please call Luke Maschinot at 404-727-1338 or email luke.j.maschinot@emory.edu.

Emory Healthy Aging Study website

Caregiving for a loved one with Alzheimer’s or another form of neurodegenerative disease is usually a new role. Some people gradually take on the role of caregiver as their spouse or parent has increasing memory or thinking problems. Others are thrust into the role. Perhaps your mother died who was caring of your father. Suddenly you become your father’s caregiver, a role for which you had no preparation.

When you have a family member with Alzheimer’s or another neurodegenerative disease there are new skills to learn and new resources that will be needed. It will be important to “plan for the future”.